Analysts have been eager to weigh in on the Healthcare sector with new ratings on ProKidney (PROK – Research Report), Gritstone Oncology (GRTS – Research Report) and MicroPort Scientific (MCRPF – Research Report).
ProKidney (PROK)
In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on ProKidney, with a price target of $6.00. The company’s shares closed last Tuesday at $1.77, close to its 52-week low of $1.12.
According to TipRanks.com, Zelin is a 5-star analyst with an average return of
Currently, the analyst consensus on ProKidney is a Moderate Buy with an average price target of $4.00.
See the top stocks recommended by analysts >>
Gritstone Oncology (GRTS)
BTIG analyst Kaveri Pohlman maintained a Buy rating on Gritstone Oncology yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $2.04.
According to TipRanks.com, Pohlman is a 4-star analyst with an average return of
Gritstone Oncology has an analyst consensus of Strong Buy, with a price target consensus of $9.40, implying a 351.9% upside from current levels. In a report issued on March 1, JMP Securities also initiated coverage with a Buy rating on the stock with a $4.00 price target.
MicroPort Scientific (MCRPF)
Nomura analyst Jialin Zhang maintained a Hold rating on MicroPort Scientific today and set a price target of HK$7.19. The company’s shares closed last Friday at $0.97, close to its 52-week low of $0.80.
According to TipRanks.com, Zhang is ranked #8490 out of 8757 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for MicroPort Scientific with a $0.92 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PROK:
